Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

Dr. Shadman introduces sonrotoclax as a next-generation selective BCL-2 inhibitor approved for mantle cell lymphoma, with emerging CLL data in combination with zanubrutinib. Phase 1b studies demonstrate a 98% undetectable MRD rate in the first-line setting, which was dramatically higher than the 30% to 45% undetectable MRD rates seen with venetoclax plus BTK inhibitor combinations in comparable studies.

This cross-trial comparison must be interpreted cautiously, but the magnitude of difference generates substantial hypothesis that sonrotoclax-zanubrutinib may represent the most effective oral doublet for CLL. High undetectable MRD rates in both IGHV-unmutated and del(17p)/TP53-mutated high-risk patients add to the interest, as these populations historically achieve lower undetectable MRD rates.

Two CELESTIAL phase 3 trials are testing this hypothesis: CELESTIAL-1 (completed enrollment) compares sonrotoclax-zanubrutinib versus venetoclax-obinutuzumab, and CELESTIAL-2 (currently accruing) compares sonrotoclax-zanubrutinib versus acalabrutinib-venetoclax as the first oral doublet head-to-head comparison stratified by IGHV and TP53 status. Both are powered for PFS superiority.

Important practical advantages include simplified ramp-up schedules with dedicated prospective feasibility studies underway, and early data showing extremely low clinical TLS rates. Dr. Shadman hopes sonrotoclax development will also catalyze improved venetoclax utilization broadly, as BCL-2 inhibitor use in frontline CLL currently plateaus at approximately 30% of eligible patients. The panel acknowledges industry deserves credit for designing CLL trials with contemporary, clinically relevant comparator arms; acalabrutinib-venetoclax was just FDA-approved, making CELESTIAL-2 immediately relevant.